Filippo Russo

Dr. Filippo Russo

CEINGE Advanced Biotechnologies, Naples, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSabrina Chiloiro
Sabrina Chiloiro
FRFilippo Russo
Filippo Russo
TTTommaso Tartaglione
Tommaso Tartaglione
Ettore CapoluongoEttore Capoluongo
Ettore Capoluongo
Hypophysitis is a rare and potentially life-threatening disease, characterized by an elevated risk of complications, such as the occurrence of acute central hypoadrenalism, persistent hypopituitarism, or the extension of the inflammatory process to the neighboring neurological structures. In recent years, a large number of cases has been described. The diagnosis of hypophysitis is complex because it is based on clinical and radiological criteria. Due to this, the integration of molecular and genetic biomarkers can help physicians in the diagnosis of hypophysitis and play a role in predicting disease outcome. In this paper, we review current knowledge about molecular and genetic biomarkers of hypophysitis with the aim of suggesting a possible integration of these biomarkers in clinical practice.

28 March 2023 in Biology
Verified
Journal Article
Open access
PDF file
RCRosa Catapano
Rosa Catapano
RSRaffaele Sessa
Raffaele Sessa
Silvia TrombettiSilvia Trombetti
Silvia Trombetti
ECElena Cesaro
Elena Cesaro
FRFilippo Russo
Filippo Russo
MGMichela Grosso
Michela Grosso
The erythroid transcriptional factor Krüppel-like factor 1 (KLF1) is a master regulator of erythropoiesis. Mutations that cause KLF1 haploinsufficiency have been linked to increased fetal hemoglobin (HbF) and hemoglobin A2 (HbA2) levels with ameliorative effects on the severity of β-thalassemia. With the aim of determining if KLF1 gene variations might play a role in the modulation of β-thalassemia, in this study we screened 17 subjects showing a β-thalassemia-like phenotype with a slight or marked increase in HbA2 and HbF levels. Overall, seven KLF1 gene variants were identified, of which two were novel. Functional studies were performed in K562 cells to clarify the pathogenic significance of these mutations. Our study confirmed the ameliorative effect on the thalassemia phenotype for some of these variants but also raised the notion that certain mutations may have deteriorating effects by increasing KLF1 expression levels or enhancing its transcriptional activity. Our results indicate that functional studies are required to evaluate the possible effects of KLF1 mutations, particularly in the case of the co-existence of two or more mutations that could differently contribute to KLF1 expression or transcriptional activity and consequently to the thalassemia phenotype.

6 July 2026 in American Journal of Hematology
Verified
Journal Article
Closed access
AIAnthony Iscaro
Anthony Iscaro
SLSimona Leoni
Simona Leoni
FRFilippo Russo
Filippo Russo
VBValentina Brancaleoni
Valentina Brancaleoni
BRBarbara Eleni Rosato
Barbara Eleni Rosato
Roberta RussoRoberta Russo
Roberta Russo

29 July 2026 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
FRFilippo Russo
Filippo Russo
Silvia TrombettiSilvia Trombetti
Silvia Trombetti
MSMaria Rosaria Storino
Maria Rosaria Storino
RSRaffaele Sessa
Raffaele Sessa
CFCarmela De Felice
Carmela De Felice
MGMichela Grosso
Michela Grosso
Click on the article title to read more.